Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Song, M. Baer, R. Srinivasan, J. Lima, G. Yarranton, C. Bebbington, S. Lynch (Shanghai, China; San Francisco, United States Of America). PcrV antibody prophylaxis in combination with antibiotic therapy reduces lung injury and improves survival in pseudomonas aeruginosa infected mice. Eur Respir J 2011; 38: Suppl. 55, 2565

Member's Comments

No comment yet.

Related content which might interest you: Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020 Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model Source: Eur Respir J 2007; 29: 965-968 Year: 2007 The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Effect of long term treatment with azithromycin on clinical status and lung function parameters in cystic fibrosis patients colonised by pseudomonas aeruginosa Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research Year: 2009 An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005 Effects of PC945, a novel antifungal agent optimised for lung delivery, on Candida albicans lung infection in mice Source: Virtual Congress 2020 – Translational science in respiratory infections Year: 2020 Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Source: Eur Respir J , 49 (4)  1600851; DOI: 10.1183/13993003.00851-2016 Year: 2017 Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving P. aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Azithromycin protects bronchial epithelial integrity after Pseudomonas aeruginosa infection independent of bactericidal activity Source: Annual Congress 2008 - Best of lung epithelial cells 2008 Year: 2008 Panobacumab, a fully human monoclonal antibody for ventilator associated pneumonia caused by Pseudomonas aeruginosa Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017